This Project Grant award of $2,312,085, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the molecular mechanisms linking HIV infection and opioid use disorder that contribute to neuroinflammation and HIV-associated neurocognitive disorders (HAND). The research, led by the Trustees of Boston University's Medical Campus, will utilize primary human iPSC-derived microglia cultures to...
The National Institute on Drug Abuse (NIDA) awarded a Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $3,086,472 to the University of Rhode Island on September 15, 2024. The objective of this 5-year project is to evaluate the spillover effects of HIV interventions among marginalized populations, particularly young Black men who have sex with men (BMSM), who use illicit substances. The project will leverage data from three existing network studies in Chicago,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,223,769 to the University of California, San Diego (UCSD) to conduct research on the intertwined mechanisms of HIV and opioid use on mitochondrial-mediated inflammasome activation and neurotoxicity. The research aims to elucidate how the convergence of HIV infection and opioid use leads to more severe neurological consequences, including...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $234,000.00 to Georgetown University to conduct research on the effect of opioids on HIV transcription and latency. The key objectives are to understand the mechanisms by which opioids such as fentanyl, morphine, and methadone influence HIV proviral transcription in microglia and astrocytes, as well as to longitudinally measure and...
The National Institute on Drug Abuse (NIDA) awarded a $687,416 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA. The grant supports research to develop therapeutically effective latency-promoting agents (LPAs) that can "block" HIV reactivation and "lock" HIV in a silenced state, even in the presence of addictive substances, for people living...
This $585,975 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to discover and functionally characterize long non-coding RNAs (lncRNAs) in opioid use disorder (OUD) within the context of HIV at single-cell resolution. The University of Massachusetts Medical School will lead this 5-year effort to systematically identify novel lncRNAs in human and mouse brain tissues affected by OUD and HIV,...
The National Institute on Drug Abuse (NIDA) awarded a $558,085 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the University of California, Irvine (UCI) to support an interdisciplinary research initiative titled "DMFV-SCORCH Project". This 5-year project aims to uncover multi-scale dysregulations resulting from HIV and opioid use disorder (OUD) through population-scale single-nuclei sequencing data analysis and functional validations using advanced genomic...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is intended to develop effective methods for disseminating scientific evidence to policymakers in order to improve access to services that can prevent HIV transmission and overdose among people who use drugs. The $2,362,500 award, effective July 1, 2025 through June 30, 2029, will be administered by the University of California, Los Angeles...
This Project Grant award of $558,668 from the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs supports research to elucidate the shared and distinct molecular mechanisms underlying the interplay between HIV, substance use disorders (SUD), and neuropsychiatric/neurodegenerative conditions. The award to Massachusetts Institute of Technology (MIT) aims to leverage single-cell transcriptomic, epigenomic, and spatial datasets along with...
This federal Project Grant award, with ID R01DA059503, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $1,192,612 grant will fund a 5-year research project by The Miriam Hospital, a non-profit healthcare and research institution in Providence, RI, to integrate HIV prevention services into clinical care settings for people with opioid use disorder (OUD).
The key objectives of this multidisciplinary research project are to: 1) conduct a systematic assessment of healthcare utilization, HIV prevention services, and medication for OUD (MOUD) using claims and emergency department data; 2) use an evidence-based quality improvement (EBQI) approach to determine the optimal care settings and implementation strategies for integrating HIV prevention and MOUD services; and 3) test the effects of the identified strategies on reducing HIV incidence at the population level using agent-based modeling. This innovative study aims to identify effective ways to engage people with OUD in critical HIV prevention services and reduce the public health burden of both opioid use and HIV.